Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: oral antibiotics Clear all
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

NCT00627393
View directory record Official record
Conditions
Neutropenia, Infection
Interventions
Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
Drug · Biological · Device
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

NCT00671814
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701, linezolid, placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 20, 2026, 4:54 AM EDT
Not listed No phase listed Observational

Multi-institutional Trial of Non-operative Management of Appendicitis

NCT02271932
View directory record Official record
Conditions
Appendicitis
Interventions
Non-operative
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
8 Years to 17 Years · Male only
Enrollment
1,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome

NCT03452189
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 20, 2026, 4:54 AM EDT
Recruiting Early Phase 1 Interventional

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

NCT06197308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
oral vancomycin and oral amoxicillin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 76 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

NCT06131021
View directory record Official record
Conditions
Periodontitis, Periodontal Diseases, Periodontal Pocket
Interventions
Amoxicillin, Metronidazole, Placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
35 Years and older
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 4:54 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

NCT01110408
View directory record Official record
Conditions
Complicated Urinary Tract Infections or Pyelonephritis
Interventions
Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 20, 2026, 4:54 AM EDT
Recruiting Phase 2 Interventional

MMP-9 Inhibition for Recalcitrant Wet AMD

NCT04504123
View directory record Official record
Conditions
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Doxycycline Hyclate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT03788967
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBPM-PI-HBr, Ertapenem, Dummy Infusion, Dummy tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
La Mesa, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 20, 2026, 4:54 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

NCT05298358
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
RIC alloBMT w PTCy in refractory SSc
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

NCT02257918
View directory record Official record
Conditions
Gonorrhoea
Interventions
AZD0914, Ceftriaxone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 20, 2026, 4:54 AM EDT
Terminated Not applicable Interventional

Discharged With Indwelling Chest Tube and Valve

NCT03943511
View directory record Official record
Conditions
Prolonged Air Leak
Interventions
Oral Antibiotics-Close Monitoring, Standard of Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

NCT01271998
View directory record Official record
Conditions
Bacterial Infection
Interventions
TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 20, 2026, 4:54 AM EDT
Recruiting Phase 4 Interventional

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

NCT06953271
View directory record Official record
Conditions
Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)
Interventions
Methenamine Hippurate, Typically prescribed oral antibiotic prophylaxis
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration

NCT01929460
View directory record Official record
Conditions
Pancreatic Cysts
Interventions
Ciprofloxacin, Placebo (for ciprofloxacin)
Drug · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 20, 2026, 4:54 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Novel Combination Oral Agent to Treat Acne Vulgaris

NCT01301586
View directory record Official record
Conditions
ACNE VULGARIS
Interventions
Doxycycline and S-equol, Doxycycline
Drug
Lead sponsor
Nexgen Dermatologics, Inc.
Industry
Eligibility
13 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Rolling Hills Estates, California • Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CAMBRA - PBRN Caries Management By Risk Assessment In A Practice-Based Research Network

NCT01176396
View directory record Official record
Conditions
Dental Caries
Interventions
Caries prevention active intervention, control treatment
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 20, 2026, 4:54 AM EDT
Recruiting Phase 3 Interventional

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

NCT05699174
View directory record Official record
Conditions
Infections, Infected Wound, Nonunion of Fracture, Injury Leg, Amputation, Internal Fixation; Complications, Infection or Inflammation, Fracture, Lower Extremity Fracture, Antibiotic Side Effect
Interventions
Standard of Care PO (oral) antibiotics, Standard of Care Intravenous (IV) antibiotics
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Minneapolis, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 4:54 AM EDT
Terminated Early Phase 1 Interventional

Geisinger Antibiotic Allergy Pilot Program: Assess and Address

NCT05464615
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Amoxicillin
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Danville, Pennsylvania • Lewiston, Pennsylvania • Scranton, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 20, 2026, 4:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

NCT06672978
View directory record Official record
Conditions
Acute Pyelonephritis, Complicated Urinary Tract Infection
Interventions
Meropenem-Vaborbactam, Antibiotics
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Industry
Eligibility
3 Months to 11 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Little Rock, Arkansas • Orange, California • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Not applicable Interventional Results available

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

NCT00963924
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo, Cognitive Remediation
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 20, 2026, 4:54 AM EDT
Not listed Phase 4 Interventional

Antibiotics to Decrease Post ERCP Cholangitis

NCT03087656
View directory record Official record
Conditions
Cholangitis
Interventions
Ceftriaxone, Levofloxacin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 20, 2026, 4:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

NCT04208958
View directory record Official record
Conditions
Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
Interventions
VE800, Nivolumab, Vancomycin Oral Capsule
Biological · Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 20, 2026, 4:54 AM EDT
Terminated Phase 1 Interventional

FMT for MDRO Colonization After Infection in Renal Transplant Recipients

NCT02922816
View directory record Official record
Conditions
Infection Due to Resistant Organism
Interventions
Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling, Fasting
Biological · Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 20, 2026, 4:54 AM EDT